President Trump’s sweeping tariffs on automobiles drew a sharp reaction on Thursday from leaders in Germany and France, who called on the European Union to hit back firmly against measures that they said would harm the United States and Europe, and global trade as a whole.

Mr. Trump announced on Wednesday that he would impose a 25 percent tariff on cars and car parts shipped to the United States, putting pressure on America’s top trade allies around the globe. The tariffs, which he said were permanent, will take effect on April 3.

President Emmanuel Macron of France said Thursday that he had told Mr. Trump the day before that tariffs were “not a good idea.” France would work with the European Commission on a “riposte,” he added, the goal of which would be “to find an accord to dismantle the tariffs” and getting the U.S. president to “reconsider.”

In Germany, whose auto industry is a huge exporter to the United States and faces a blow, the economy minister, Robert Habeck, said it was “crucial that the E.U. delivers a decisive response to the tariffs,ijogo slots” adding: “It must be clear that we will not back down.”

In a statement, Germany’s chancellor, Olaf Scholz, called Mr. Trump’s tariff decision “wrong.” “The U.S. is thus embarking on a path that will only end with losers,” he said. “Because tariffs and isolation cost prosperity for everyone.”

The American market is crucial for Germany’s biggest automakers, including BMW, Mercedes-Benz and Volkswagen. German automakers have long been a target of Mr. Trump’s ire.

We are having trouble retrieving the article content.

Please enable JavaScript in your browser settings.

Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.

AstraZeneca, which makes the treatment, said it would start a FluMist Home website, where people can fill out a questionnaire that will be reviewed by a pharmacist before the treatment is shipped to a person’s home. The mist will remain available from prescribers as an in-office treatment. The current out-of-pocket cost for a dose is about $35 to $45, but may be less depending on insurance coverage.

Thank you for your patience while we verify access.

Already a subscriber? Log in.

Want all of The Times? Subscribe.888pg